Microbix Biosystems Inc. (MBX.TO)
| Previous Close | 0.3200 |
| Open | 0.3150 |
| Bid | 0.3150 x 0 |
| Ask | 0.3200 x 0 |
| Day's Range | 0.3100 - 0.3200 |
| 52 Week Range | 0.2300 - 0.4500 |
| Volume | |
| Avg. Volume | 62,304 |
| Market Cap | 43.973M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 10.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Sept 02, 1999 |
| 1y Target Est | N/A |
- GlobeNewswire
Microbix Reports Strong Results for Q2 Fiscal 2024
Revenues of $5.6 million and Net Income of $0.4 millionMISSISSAUGA, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024 (“Q2” and “H1”), with strong growth in sequential and year-over-year quarterly revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients
- GlobeNewswire
Microbix Schedules Release of Results for Q2 Fiscal 2024
Results Release and Webinar Discussion on Morning of May 15, 2024 MISSISSAUGA, Ontario, May 08, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its second quarter of fiscal 2024 ended March 31, 2024 (“Q2 2024”) prior to the start of trading on May 15, 2024. Furthermore, at 10:00 AM ET on that day, Micro
- GlobeNewswire
Microbix Collaborator Introduces New Lab Accreditation Program
Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted InfectionMISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that Labquality Ltd., a collaborator and customer, is presenting results of its use of Microbix Quality Assessment Products (“QAPs™”) for accreditation of clinical labs for conducting molecular (“MDx”) tests for antimicrobial-resis
